Incyte CORP Schedule 13G passive stakes

Dodge & Cox has reported a beneficial ownership of 12,252,356 shares, representing 6.2% of Incyte Corporation's common stock, as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 12,591,630 shares, representing 6.32% of Incyte Corp's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Incyte Corp, reporting zero beneficial ownership following an internal realignment that disaggregated reporting.

State Street Corporation has reported a 5% beneficial ownership stake in Incyte Corp's common stock as of September 30, 2025.

Incyte Corporation has reported a 9.9% beneficial ownership stake in Prelude Therapeutics, Inc., holding 4,372,124 shares of common stock.

BlackRock, Inc. has reported an increased beneficial ownership of 7.8% in Incyte Corporation's common stock as of September 30, 2025.